News + Font Resize -

Teva gets FDA nod for deferoxamine mesylate for Injection USP
Jerusalem | Thursday, April 6, 2006, 08:00 Hrs  [IST]

The US Food and Drug Administration has granted approval for Teva Pharmaceutical Industries' ANDA for Deferoxamine Mesylate for Injection USP, 500 mg/vial and 2 g/vial. Shipment of this product will begin immediately.

Teva's Deferoxamine Mesylate for Injection is the AP-rated generic equivalent of Novartis' Desferal for Injection, a product indicated for acute treatment of iron intoxication and chronic iron overload due to transfusion-dependent anemias.

Total annual sales of Deferoxamine Mesylate for Injection are approximately $43 million.

Post Your Comment

 

Enquiry Form